Business Context and Reporting Period
This Form 8-K Current Report from Medicus Pharma Ltd. (MDCX) covers events occurring on November 28, 2025, and December 1, 2025. The filing primarily addresses significant changes in executive leadership, specifically the resignation of the Chief Financial Officer and the appointment of a successor.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on personnel changes and related compensation arrangements.
Material Changes
- Resignation of CFO: James Quinlan resigned as Chief Financial Officer and employee effective November 28, 2025. He had been on medical leave since September 12, 2025.
- Appointment of CFO: Carolyn Bonner, who served as Acting CFO since September 12, 2025, was appointed Chief Financial Officer effective December 1, 2025. She will continue to serve as President of the Company.
- Compensation Agreement: An amended and restated employment agreement was executed for Ms. Bonner with a five-year term. Her annual base salary is set at $395,000.
- Bonus Structure: Ms. Bonner is eligible for a discretionary annual bonus ranging from 60% of her base salary in year one to 100% in year five.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, operational outlook, or discuss specific business risks beyond the leadership transition. Ms. Bonner brings prior experience as President & CEO of PCL, Inc. and roles at Rosetta Genomics Ltd. and Inform Diagnostics, Inc. The Company is designated as an emerging growth company.
Investor Verification Checklist
- Verify the effective dates of the CFO transition (Nov 28 resignation, Dec 1 appointment).
- Review the specific terms of the new employment agreement, including the escalating bonus targets (60% to 100% of base salary).
- Confirm the status of the Company's financial reporting given the recent departure of the CFO and the interim period of medical leave.
- Check for any subsequent filings regarding stock option grants to Ms. Bonner, which are noted as discretionary.